Description
How It Works
MOTS-C interacts directly with cellular energy pathways to:
- Increase AMPK Activation: Promoting a healthy metabolic state and glucose utilization.
- Enhance Fat Oxidation: Assisting the body in using fat as an energy source.
- Mitochondrial Efficiency: Boosting mitochondrial biogenesis and cellular longevity.
- Improve Insulin Sensitivity: Helping to regulate blood sugar levels and uptake.
Your Treatment Program
MOTS-C is delivered through a doctor-guided program designed to support safe and effective use.
What’s Included
- Medical Consultation: A detailed review of your health, history, and goals.
- Personalized Protocol: A treatment plan tailored to your individual needs.
- Clinical Assessment: Additional testing may be recommended where appropriate.
- Guided Administration Plan: Structured scheduling based on medical evaluation.
- Ongoing Support: Monitoring and adjustments throughout your program.
Program Timeline
Standard cycles are structured over a 4 to 8-week period, with the option to repeat the cycle after a short rest period.
Important Information
- This program is provided under medical supervision only.
- Suitability is determined following consultation.
- Caution: Should be avoided in those with severe liver/kidney disease or active cancer.
- This information is for educational purposes and does not replace medical advice.
FAQs about MOTS-C
MOTS-c is a mitochondrial signaling peptide that acts as a regulator for your metabolism and how your body responds to stress.
Yes, it enhances fat oxidation, improves insulin sensitivity, and increases glucose utilization, making it a powerful support tool for weight management.
Definitely. It is known to boost mitochondrial biogenesis and athletic endurance, helping the body perform more efficiently during exercise.
It is best injected in the morning in a fasted state or immediately before exercise to optimize mitochondrial activation.
A common schedule is 5 mg injected twice weekly (e.g., Monday and Thursday) for a cycle of 4-8 weeks.
